Related Experiment Videos
Isozyme patterns and protein profiles in neuromuscular disorders
Journal of Medical Genetics
|June 1, 1982
Summary
Biochemical abnormalities in neuromuscular disorders often reflect a reversion to fetal gene expression patterns in existing muscle tissue. Phosphoglycerate mutase and creatine kinase are sensitive indicators of muscle disease severity.
Area of Science:
- Biochemistry
- Molecular Biology
- Neurology
Background:
- Neuromuscular disorders encompass a range of conditions affecting muscle function.
- Understanding the molecular basis of these disorders is crucial for diagnosis and treatment.
- Isozyme patterns and protein profiles can serve as biomarkers for cellular changes.
Purpose of the Study:
- To investigate the biochemical alterations in muscle tissue from patients with neuromuscular disorders.
- To determine if these alterations correlate with disease severity and pattern of gene expression.
- To identify sensitive enzymatic markers for muscle disease.
Main Methods:
- Analysis of isozyme patterns for six enzymes in muscle biopsy specimens.
- Examination of polypeptide profiles of soluble proteins from muscle tissue.
- Biochemical analysis of samples from 74 patients with diverse neuromuscular disorders.
Main Results:
- Approximately 50% of samples exhibited abnormal isozyme or protein profiles.
- Biochemical abnormalities correlated with the severity of the neuromuscular disorder.
- Observed changes indicated a reversion to fetal gene expression in existing muscle fibers.
- Phosphoglycerate mutase and creatine kinase were identified as the most sensitive enzyme markers.
- Muscle creatine kinase isozyme pattern changes did not correlate with serum creatine kinase levels.
Conclusions:
- Muscle biopsy analysis reveals significant biochemical abnormalities in neuromuscular disorders.
- These abnormalities represent a fetal gene expression reversion in mature muscle.
- Specific enzymes like phosphoglycerate mutase and creatine kinase are valuable indicators of muscle pathology.